The investment will be primarily aimed at updating production and releasing new dosage forms.
"We intend to maintain the leading positions Sintez currently occupies on the antibiotics market, which is why most of the funding will be invested in the production of new generation, semi-synthetic antibiotics, said CEO Sergey Klykov. "Another major investment will be the launch of a new line of gels, as this dosage form is steadily gaining popularity with consumers. We expect production to increase by at least 25%, this year. Our IT system will also undergo significant modernization with the introduction of a new product labeling system. We will also continue developing our energy complex, which will ensure an autonomous supply of thermal energy, if necessary. Another part of the funds will be allocated to quality control in our laboratories."